Eli Lilly, the manufacturer of the popular weight-loss drug Mounjaro, has announced a significant price increase for its product in the UK, effective September 1st. The wholesale cost of a month's supply of the highest dose is set to soar from £122 to £330, a substantial hike that has caused widespread panic among slimmers. Lilly justified the increase by stating that Mounjaro was initially launched at a price "significantly below the European average to prevent delays in NHS availability" and that this adjustment is necessary "to ensure fair global contributions to the cost of innovation." While the price increase does not affect the heavily discounted rate paid by the NHS for prescribed patients, it impacts an estimated 1.5 million people in the UK on weight loss drugs, with more than half of them on Mounjaro, and approximately nine out of ten paying privately. Many users have expressed devastation on social media, feeling they can no longer afford the "life-changing" treatment.

For those currently paying privately, obtaining Mounjaro on the NHS is not straightforward. NHS guidelines for weight-loss jab prescriptions are strict, requiring patients to have a Body Mass Index (BMI) of at least 40 (severely obese) alongside four obesity-related conditions such as high blood pressure, high cholesterol, or diabetes. While these criteria will slightly broaden in the coming years, private clinics offer Mounjaro to patients with a BMI over 30, or 27 with one weight-related condition. Experts note that switching from private to NHS treatment will not happen overnight, requiring face-to-face GP appointments for eligibility assessment and ongoing monitoring for at least the first year.

Faced with unaffordable Mounjaro prices, many users are considering switching to alternative medications, with Wegovy being the most likely option. Wegovy, which contains the ingredient semaglutide and is manufactured by Novo Nordisk, has seen a surge in demand due to its comparatively lower cost in the UK private market (a 2.4 mg maintenance dose costs around £250 to £300 per month). Pharmacists and medical experts emphasize that switching medications should only be done under strict medical supervision to prevent severe side effects and avoid weight regain. A direct 'mg-for-mg' conversion between Mounjaro and Wegovy is not possible due to their differing compositions and strengths.

Clinical trials indicate Mounjaro's superior effectiveness, achieving an average weight loss of 20-22.5 percent over 72 weeks, compared to Wegovy's 14-17.5 percent. This difference is attributed to Mounjaro mimicking two hormones released after a meal (GLP-1 and peptide YY) that control appetite, whereas Wegovy mimics only one (GLP-1). While both are highly effective, patients switching from Mounjaro to Wegovy may experience more gastrointestinal side effects such as nausea or vomiting. Common side effects for new GLP-1 medications also include diarrhoea, constipation, and headaches.

To safely switch, patients are generally advised to take their next semaglutide dose one week after their last Mounjaro injection, effectively replacing it without a prolonged break to avoid a "hunger rebound." However, there is no direct dose conversion, so patients might start on a low dose of semaglutide and gradually increase. Experts strongly warn against abruptly stopping weight loss jabs due to risks of side effects and regaining lost weight. Furthermore, they caution against attempting to "microdose" remaining pens or purchasing drugs from unregulated "cowboy" operators, as these practices can lead to serious health complications, infections, and reduced drug effectiveness. Patients must completely come off Mounjaro, typically for about seven days, before starting a new GLP-1 jab to prevent massively increased side effects.

Amidst these challenges, a new "natural Mounjaro" pill called Elcella has emerged, developed by British scientists. This £49-a-week capsule, priced at £535.50 for a three-month supply, is made from just three natural oils: linseed oil (flaxseed), coconut oil, and MCT oil. Elcella works by triggering the natural release of gut hormones GLP-1 and peptide YY in the colon through a special coating that prevents breakdown in the stomach, thereby sending signals of fullness to the brain without replicating synthetic hormones.

Clinical trials of Elcella have shown promising results, with patients cutting calorie intake by 18 percent and losing an average of 1st 1lb (approximately 7 kg) in 12 weeks, with no reported side effects. This contrasts with synthetic drugs like Ozempic, which showed an average loss of 13lb over 40 months. Elcella is available online without a prescription and, unlike pharmaceutical jabs, does not create dependency. Users have reported additional benefits such as healthier hair and nails, less stomach pain, and more regular bowel movements. A case study highlighted a patient, Clare, who lost over 3st (approximately 19 kg) and 18cm from her waist in three months, transforming her body and overcoming constant hunger.

The search for effective and affordable weight management solutions is critical given that around two in three adults in the UK are overweight or obese, contributing to high rates of type 2 diabetes and being the second biggest cause of cancer in the country. The rising costs of pharmaceutical weight loss injections like Mounjaro underscore the growing need for accessible and safe alternatives like Elcella to combat the global obesity epidemic.